Loading...
Use of anticoagulant and antiplatelet agents can increase the risk for rebleeding in patients with lower gastrointestinal bleeding (LGIB). To characterize that risk, researchers analyzed prospectively collected data from over 2000 consecutive patients presenting with LGIB in U.K. hospitals. Patients were grouped as users of direct oral anticoagulants (DOACs), single antiplatelet therapy, dual antiplatelet therapy (DAPT), warfarin, or none of these medications (unexposed).
DAPT users had the highest rate of in-hospital rebleeding (38%, significantly higher compared with unexposed patients), followed by single antiplatelet users (28%). The warfarin and DOAC groups had rebleeding rates similar to that in the unexposed group (23%, 20%, and 19%, …